Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
11.22
+0.49 (4.57%)
At close: Jun 27, 2025, 4:00 PM
11.33
+0.11 (0.98%)
After-hours: Jun 27, 2025, 5:26 PM EDT
Theravance Biopharma Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Theravance Biopharma stock ranges from a low of $9.00 to a high of $25. The average analyst price target of $16.6 forecasts a 47.95% increase in the stock price over the next year.
Price Target: $16.60 (+47.95%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Theravance Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $24 → $25 | Strong Buy | Maintains | $24 → $25 | +122.82% | Jun 27, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +113.90% | Jun 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +33.69% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +33.69% | Feb 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +33.69% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
92.18M
from 64.38M
Increased by 43.18%
Revenue Next Year
81.48M
from 92.18M
Decreased by -11.61%
EPS This Year
-0.47
from -1.15
EPS Next Year
-1.20
from -0.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 101.9M | 90.0M | 134.8M | ||
| Avg | 92.2M | 81.5M | 109.4M | ||
| Low | 74.5M | 67.9M | 76.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 58.2% | -2.4% | 65.5% | ||
| Avg | 43.2% | -11.6% | 34.2% | ||
| Low | 15.7% | -26.3% | -5.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.41 | -0.85 | -0.05 | ||
| Avg | -0.47 | -1.20 | -0.32 | ||
| Low | -0.55 | -2.13 | -0.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.